Abstract
To provide appropriate levels of stimulation, retinal prostheses must be calibrated to an individual’s perceptual thresholds (‘system fitting’), despite thresholds varying drastically across subjects, across electrodes within a subject, and over time. Although previous work has identified electrode-retina distance and impedance as key factors affecting thresholds, an accurate predictive model is still lacking. To address these challenges, we 1) fitted machine learning (ML) models to a large longitudinal dataset with the goal of predicting individual electrode thresholds and deactivation as a function of stimulus, electrode, and clinical parameters (‘predictors’) and 2) leveraged explainable artificial intelligence (XAI) to reveal which of these predictors were most important. Our models accounted for up to 77% of the perceptual threshold response variance and enabled predictions of whether an electrode was deactivated in a given trial with F1 and AUC scores of up to 0.740 and 0.913, respectively. Deactivation and threshold models identified novel predictors of perceptual sensitivity, including subject age, time since blindness onset, and electrode-fovea distance. Our results demonstrate that routinely collected clinical measures and a single session of system fitting might be sufficient to inform an XAI-based threshold prediction strategy, which may transform clinical practice in predicting visual outcomes.
- Retinal prostheses
- perceptual thresholds
- electrode deactivation
- explainable AI
- Argus II
Competing Interest Statement
The authors were collaborators with Second Sight Medical Products, Inc. (now Vivani Medical, Inc.), the company that developed, manufactured, and marketed the Argus II Retinal Prosthesis System referenced within this article. Second Sight had no role in study design, data analysis, decision to publish, or preparation of the manuscript.
Funding Statement
This work was supported by the National Eye Institute of the National Institutes of Health under Award Number R00-EY029329.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A subset of the data was previously collected as part of the Argus II Feasibility Protocol (Clinical Trial ID: NCT00407602). Our study, which did not involve human subjects research, was deemed exempt from institutional review board (IRB) approval by the IRB at the University of California, Santa Barbara.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This work was supported by the National Eye Institute of the National Institutes of Health under Award Number R00-EY029329. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
We would like to thank Arup Roy and Jessy Dorn (who were with Second Sight Medical Products, Inc.) for providing the raw data as well as Profs. Ione Fine and Geoff Boynton at the University of Washington for insightful discussions during an earlier iteration of this work.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos